In this section
This document guides how to prescribe, order, administer and manage patients receiving intravenous immunoglobulin (IVIg) at the RCH.
Record the consent for the administration of IVIg on the Patient Consent to Blood Products MR634/A.
Inform the patient of:
Consent is valid for the duration of the admission. However, consent for patients receiving regular IVIg is valid for 12 months. This should be indicated on the MR634/A.
Print and provide the patient/family information explaining IVIg. See table below for links.
Administration rates vary between products and presentations.
IVIg products and presentations are not interchangeable.
Privigen AU
(Australian product)
Kiovig 10% (Imported product)
Flebogamma 5% DIF
(Imported product)
Flebogamma 10% DIF
Gammunex 10%
5g in 50 mL
10 g in 100 mL
20g in 200 mL
10g in 100 mL
30g in 300 mL
2.5g in 50 mL
5g in 100 mL
10g in 200 mL
20g in 400 mL
Incremental rates:
increase every 30 minutes only if tolerated
0.6 mL/kg/hr
1.2 mL/kg/hr
2.4 mL/kg/hr
3.6 mL/kg/hr
1 mL/kg/hr
1.5 mL/kg/hr
2 mL/kg/hr
3 mL/kg/hr
4 mL/kg/hr
1.8 mL/kg/hr
3.0 mL/kg/hr
4.2 mL/kg/hr
4.8 mL/kg/hr
5.4 mL/kg/hr
6.0 mL/kg/hr
3.6 ml/kg/hr
Maximum 360 mL/hr
0.9% Normal Saline may be
used to flush the IV line.
Storage*
(All products stored in blood bank)
Limited experience at the RCH with infusing
Kiovig, Flebogamma 5%, Flebogamma 10%, Gamunex 10% or Octogam 10%.
Foot Notes:
Baseline
(within 60 minutes before commencing transfusion)
Temperature, pulse, respiratory rate, blood pressure, SaO2 and IV pump volume.
Observe the patient post the infusion.
Adverse events or near miss:
Report any adverse events or near miss via VHIMS. These will be reported to the Transfusion Committee who will report to CSL and the TGA as needed.
Overdose of IVIg may lead to fluid overload and hyperviscosity, particularly in patients with renal impairment.